Page 81 - Read Online

Miliotis et al. J Cancer Metastasis Treat 2020;6:13 I http://dx.doi.org/10.20517/2394-4722.2020.12 Page 15 of 15

susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 2015;4:e1008824.
103. Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells
and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol 2009;217:21-31.
104. Sasaki S, Nishikawa J, Sakai K, Iizasa H, Yoshiyama H, et al. EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1
interactions. Gastric Cancer 2019;22:486-96.
105. Fang W, Zhang J, Hong S, Zhan J, Chen N, et al. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma:
Implications for oncotargeted therapy. Oncotarget 2014;5:12189-202.
106. Su S, Zou Z, Chen F, Ding N, Du J, et al. CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of
EBV positive gastric cancer. OncoImmunology 2016;6:e1249558.
107. Nakayama A, Abe H, Kunita A, Saito R, Kanda T, et al. Viral loads correlate with upregulation of PD-L1 and worse patient prognosis in
Epstein-Barr Virus-associated gastric carcinoma. PLoS One 2019;14:e0211358.
108. Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, et al. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-
infected cells and activates signaling from Toll-like receptor 3. J Exp Med 2009;206:2091-9.
109. Lemery S, Keegan P, Pazdur R. First FDA approval agnostic of cancer site - when a biomarker defines the indication. N Engl J Med
2017;377:1409-12.